Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.41 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.41 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.41 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591629 | 0.90 | MAOB (0.55) | MAP4K4MAOBFFAR1CYP2C9CYP2C19 | |
| Cadaverine Tartrate SCHEMBL9936744 | 0.87 | ALDH1A1 (0.47) | FFAR1L3MBTL1 | |
| Cadaverine Tartrate SCHEMBL9938636 | 0.86 | ALDH1A1 (0.44) | FFAR1MEN1KMT2A | |
| Cadaverine Tartrate SCHEMBL9938552 | 0.86 | FFAR1 (0.45) | FFAR1PPARGPPARAL3MBTL1PLAAT3 | |
| SCHEMBL1990535 | 0.85 | CYP2C9 (0.57) | FFAR1CYP2C9CYP2C19PDPK1MEN1 | |
| Cadaverine Tartrate SCHEMBL3634787 | 0.82 | MAOB (0.49) | MAOBFFAR1PPARGPPARAPDPK1 | |
| Cadaverine Tartrate SCHEMBL3633167 | 0.81 | RARB (0.41) | FFAR1PPARGPPARA | |
| SCHEMBL5801662 | 0.78 | FFAR1 (0.71) | FFAR1HTT | |
| SCHEMBL1570003 | 0.76 | HDAC3 (0.58) | CYP2C9CYP2C19PPARGPPARAL3MBTL1 | |
| SCHEMBL11825388 | 0.76 | PPARG (0.49) | MAOBPPARGPPARACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080497-A2 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |